← Back to headlines
Stifel Reaffirms Buy Ratings for Spyre and Semtech Stocks
Investment bank Stifel has reaffirmed its buy recommendations for both Spyre Therapeutics and Semtech, citing positive rheumatoid arthritis study outcomes and strong valuation metrics for the semiconductor maker.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
